Presenter: Mai Thayer, Amgen, USA
Date: October 8, 2019
Description:
Oligonucleotides are a quickly evolving modality with strong proof of concept established in the clinic. Despite the clinical success of oligonucleotides, there is still limited understanding of ADME (absorption, disposition, metabolism and excretion) in comparison to other modalities (e.g. small molecules). The presentation will discuss the current strategies to effectively characterize oligonucleotides from early discovery into the clinical setting by discussing novel, robust, and sensitive bioanalytical tools enabling measurement of oligonucleotides in blood and tissues.
Recording of the Webinar: Click Play to View
Presenter Biography
Mai Thayer, Amgen, USA
Mai Thayer holds a Bachelor of Science degree in biochemistry and molecular biology from University of California, Davis, and a Master degree of Science in Pharmaceutical Bioengineering from the University of Washington. She has extensive experience working on teams to develop the next generations of therapeutics, including small molecules, antibodies, and RNAi molecules, and currently works within the Pharmacokinetic and Drug Metabolism group at Amgen Research in South San Francisco, CA.
References
- Application of Locked Nucleic Acid Oligonucleotides for siRNA Preclinical Bioanalytics.
Thayer MB, Lade JM, Doherty D, Xie F, Basiri B, Barnaby OS, Bala NS, Rock BM.
Sci Rep. 2019 Mar 5;9(1):3566. - Quantification of siRNA-Antibody Conjugates in Biological Matrices by Triplex-Forming Oligonucleotide ELISA.
Humphreys SC, Thayer MB, Campuzano IDG, Netirojjanakul C, Rock BM.
Nucleic Acid Ther. 2019 Jun;29(3):161-166. - Plasma and Liver Protein Binding of N-Acetylgalactosamine-Conjugated Small Interfering RNA.
Humphreys SC, Thayer MB, Lade JM, Wu B, Sham K, Basiri B, Hao Y, Huang X, Smith R, Rock BM.
Drug Metab Dispos. 2019 Oct;47(10):1174-1182.
